Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Pancreatic Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
25 drugs · 152 active trials
4 drugs · 116 active trials
8 drugs · 223 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 23 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 8, 2015 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-03 |
| Encorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 16, 2020 |
| Eribulin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-03 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-03 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-03 |
| Letrozole | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 30, 2023 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-04 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-09 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-05 |
| Plerixafor | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 25, 2017 |
| Porfimer | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1999-03 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 29, 2020 |
| Tegafur | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 5, 2014 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-12 |
| Bosutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-09 |
| Disitamab Vedotin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 17, 2024 |
| Exemestane | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 24, 2025 |
| Fruquintinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2022-02 |
| Ganetespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-12 |
| Hydroxyurea | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-03 |
| Ifosfamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-03 |
| Interferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-03 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-01 |
| MEK Inhibitor CI-1040 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-02 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 7, 2017 |
| Olaratumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 22, 2017 |
| Pomalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-11 |
| Raltitrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 1, 2019 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 17, 2012 |
| Samotolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 12, 2017 |
| Selinexor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 31, 2014 |
| Tamibarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 23, 2021 |
| Tamoxifen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 24, 2025 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-03 |
| Tarextumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-10 |
| Tazemetostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2021 |
| Trabectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-02 |
| Elimusertib | Phase 1 | Phase 1 | 2 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2021 |
| Adagrasib | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | May 3, 2023 |
| Neratinib | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Berzosertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 22, 2016 |
| Carboplatin/Paclitaxel Regimen | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-07 |
| Carmustine | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 13, 2021 |
| Guadecitabine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 7, 2018 |
| Imiquimod | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | May 11, 2016 |
| Ivosidenib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 8, 2022 |
| L19IL2 | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2026 |
| Melphalan | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 13, 2021 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.